-
What does BIOGEN BELGIUM do?
- BIOGEN is a biotechnology company that specializes in discovering, developing, and delivering innovative therapies for neurological diseases. It focuses on products for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Through its commitment to science and patient-centric solutions, BIOGEN aims to improve patient outcomes and quality of life.
-
Company number
-
0462.285.469
-
Location
- Culliganlaan 2 Machelen (Brab.) 1831 regus pegasus park,1831 diegem
-
Founding date
- Founded in 29-12-1997
-
Juridical situation
- Normale toestand
-
Juridical form
- Naamloze vennootschap
-
Type of enterprise
- Rechtspersoon
Very high risk
High risk
Average
Low risk
Very low risk
| Financial ratios | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Equity |
€
11.93M
15.5%
|
€
10.33M
22.54%
|
€
8.43M
53.62%
|
€
5.49M
|
| Turnover |
€
81.57M
-12.75%
|
€
93.49M
-11.98%
|
€
106.22M
-3.09%
|
€
109.60M
|
| Profit |
€
2.58M
-15.46%
|
€
3.05M
-33.13%
|
€
4.57M
54.9%
|
€
2.95M
|
| EBITDA |
€
2.63M
-15.12%
|
€
3.10M
-32.9%
|
€
4.62M
0.94%
|
€
4.58M
|
| Debt |
€
12.11M
-21.04%
|
€
15.34M
-43.34%
|
€
27.08M
-16.93%
|
€
32.59M
|
| Cash |
€
14.69M
0.45%
|
€
14.63M
-35.73%
|
€
22.76M
-1.64%
|
€
23.14M
|
| Employees |
36.40
-8.54%
|
39.80
-13.1%
|
45.80
4.33%
|
43.90
|
Directors
All directorsActivities according to NACEBEL codes
Activities
VAT Activities
Social Security Activities
Publications 89
All publicationsSimilar companies
Show allFrequently asked questions
The VAT number of BIOGEN BELGIUM is BE0462.285.469.
In 2023, BIOGEN BELGIUM employed 36.40 full-time equivalents (FTE).
BIOGEN BELGIUM was founded in 29-12-1997.
The official address of BIOGEN BELGIUM is Culliganlaan 2 Machelen (Brab.) 1831 regus pegasus park,1831 diegem.
The juridical form of BIOGEN BELGIUM is Naamloze vennootschap.
The legal situation of BIOGEN BELGIUM is Normale toestand.
The annual revenue of BIOGEN BELGIUM is €81,568,374.
BIOGEN is a biotechnology company that specializes in discovering, developing, and delivering innovative therapies for neurological diseases. It focuses on products for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Through its commitment to science and patient-centric solutions, BIOGEN aims to improve patient outcomes and quality of life.
Sources
Ready to start?
Find out the financial situation of potential customers, suppliers or business partners by consulting official information and key figures.
